Protecting Life and Integrity in Research Act of 2025

The Protecting Life and Integrity in Research Act of 2025 (H.R. 2075) was introduced in the House on March 11, 2025, and referred to the Committee on Energy and Commerce. A companion bill, S.987, was also introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions. The bill explicitly prohibits any federal department, agency, or office from conducting, funding, approving, or otherwise supporting research involving human fetal tissue obtained from induced abortions. It also prohibits the solicitation or knowing acquisition, receipt, or acceptance of donations of such tissue. The bill does not limit the development of new, ethical cell lines not derived from induced abortions, nor does it restrict research on human fetal tissue obtained after a miscarriage or stillbirth. This bill does not authorize or appropriate any specific funding. Instead, it imposes a restriction on the use of existing federal research funds. The mechanism is a direct prohibition, meaning any federal grants or contracts that would have supported research using human fetal tissue from induced abortions would cease or be redirected. Companies that supply such tissue or develop therapies heavily reliant on this specific research pathway would face a reduction in potential federal funding opportunities and market for their products or services. Conversely, companies specializing in alternative research methods, such as those using adult stem cells, induced pluripotent stem cells, or fetal tissue from miscarriages/stillbirths, could see increased demand for their offerings as researchers pivot. Companies like Thermo Fisher Scientific Inc. ($TMO), Danaher Corporation ($DHR), Roche Holding AG ($RHHBY), Vertex Pharmaceuticals Incorporated ($VRTX), and Gilead Sciences, Inc. ($GILD) operate in the broader biomedical research and pharmaceutical sectors. While none are exclusively reliant on the prohibited research, any restriction on research methods can shift demand for research tools, reagents, and services. $TMO and $DHR, as major suppliers of laboratory equipment and consumables, could experience shifts in demand for specific product lines. Pharmaceutical companies like $RHHBY, $VRTX, and $GILD, involved in drug discovery and development, may need to adjust research strategies if they have programs that would have utilized the prohibited tissue. The bill's impact on these companies depends on their specific exposure to this research area. Looking at recent market data, $TMO is currently at $488.19, showing a +1.7% change over 7 days but a -5.91% change over 30 days. $DHR is at $192.12, with a +4.48% change over 7 days and a -4.89% change over 30 days. $RHHBY is at $49.98, up +2.33% over 7 days but down -7.77% over 30 days. $VRTX is at $434.3, down -2% over 7 days and -5.75% over 30 days. $GILD is at $140.13, up +2.78% over 7 days but down -3.45% over 30 days. These mixed short-term movements across the sector do not directly reflect the bill's impact, as the bill is in an early legislative stage. The next legislative steps involve committee consideration in both the House and Senate. Given the early stage and the nature of the issue, passage is not guaranteed and could involve a lengthy process.